Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Income from Continuing Operations: 2020-2024

Historic Income from Continuing Operations for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$130.3 million.

  • Tango Therapeutics' Income from Continuing Operations rose 154.46% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.5 million, marking a year-over-year increase of 18.57%. This contributed to the annual value of -$130.3 million for FY2024, which is 28.07% down from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' Income from Continuing Operations is -$130.3 million, which was down 28.07% from -$101.7 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Income from Continuing Operations registered a high of -$52.0 million during FY2020, and its lowest value of -$130.3 million during FY2024.
  • Its 3-year average for Income from Continuing Operations is -$113.4 million, with a median of -$108.2 million in 2022.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first slumped by 85.81% in 2022, then grew by 5.99% in 2023.
  • Tango Therapeutics' Income from Continuing Operations (Yearly) stood at -$52.0 million in 2020, then dropped by 12.07% to -$58.2 million in 2021, then crashed by 85.81% to -$108.2 million in 2022, then rose by 5.99% to -$101.7 million in 2023, then fell by 28.07% to -$130.3 million in 2024.